Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Prevention Research
Cancer Prevention Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Article

Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Müllerian Hormone Receptor II

Suparna Mazumder, Justin M. Johnson, Valerie Swank, Nina Dvorina, Elizabeth Martelli, Jennifer Ko and Vincent K. Tuohy
Suparna Mazumder
1Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tuohyv@ccf.org mazumds@ccf.org
Justin M. Johnson
1Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
3Department of Biology, Geology and Environment Sciences, Cleveland State University, Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valerie Swank
1Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nina Dvorina
1Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Martelli
4Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Ko
5Cleveland Clinic Central Biorepository, Cleveland Clinic, Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent K. Tuohy
1Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio.
3Department of Biology, Geology and Environment Sciences, Cleveland State University, Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tuohyv@ccf.org mazumds@ccf.org
DOI: 10.1158/1940-6207.CAPR-17-0154 Published November 2017
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Epithelial ovarian carcinoma (EOC) is the most prevalent form of ovarian cancer in the United States, representing approximately 85% of all cases and causing more deaths than any other gynecologic malignancy. We propose that optimized control of EOC requires the incorporation of a vaccine capable of inducing safe and effective preemptive immunity in cancer-free women. In addition, we hypothesize that ovarian-specific self-proteins that are “retired” from autoimmune-inducing expression levels as ovaries age but are expressed at high levels in emerging EOC may serve as vaccine targets for mediating safe and effective primary immunoprevention. Here, we show that expression of the extracellular domain of anti-Müllerian hormone receptor II (AMHR2-ED) in normal tissues is confined exclusively to the human ovary, drops to nonautoimmune inducing levels in postmenopausal ovaries, and is at high levels in approximately 90% of human EOC. We found that AMHR2-ED vaccination significantly inhibits growth of murine EOC and enhances overall survival without inducing oophoritis in aged female mice. The observed inhibition of EOC growth was mediated substantially by induction of AMHR2-ED–specific IgG antibodies that agonize receptor signaling of a Bax/caspase-3–dependent proapoptotic cascade. Our results indicate that AMHR2-ED vaccination may be particularly useful in providing safe and effective preemptive immunity against EOC in women at high genetic or familial risk who have the greatest need for a preventive vaccine and ultimately in cancer-free postmenopausal women who account for 75% of all EOC cases. Cancer Prev Res; 10(11); 612–24. ©2017 AACR.

See related editorial by Shoemaker et al., p. 607

Introduction

Epithelial ovarian carcinoma (EOC) is the most lethal gynecologic malignancy and occurs predominantly in postmenopausal women who account for >75% of all cases. EOC is typically diagnosed at late stages of the disease, resulting in a high rate of recurrence following the current standard of care and a 5-year overall survival rate under 47% (1, 2). The high rate of EOC recurrence and the relatively low 5-year overall survival indicate a great need for more effective ways to control this disease.

We have advocated that optimized control of adult onset cancers like ovarian cancer requires vaccine induction of preemptive immunity that provides safe and effective primary prevention. However, immune-mediated cancer prophylaxis is currently limited to vaccination against disease-causing pathogens, including the hepatitis B virus (HBV) linked to the development of liver cancer (3) and the human papilloma virus (HPV) linked to cervical carcinoma as well as anal, penile, and oropharyngeal cancers (4). As no such confirmed pathogen is implicated in EOC tumorigenesis, we have proposed that tissue-specific self-proteins that are “retired” from autoimmune inducing levels of expression as normal tissues age but are expressed in emerging tumors may substitute for unavailable disease-associated pathogens as vaccine targets for inducing safe and effective primary immunoprevention of adult onset cancers (5).

We found that the extracellular domain of anti-Müllerian hormone receptor, type II (AMHR2-ED) has the required features of a “retired” protein for targeting safe and effective primary immunoprevention of EOC. AMHR2 is a serine/threonine kinase receptor homologous to type II receptors of the TGFβ family (6). The human AMHR2 gene contains 11 exons with seven known alternatively spliced variants producing three known coded proteins, one additional variant with protein coding features, and three noncoding transcripts with no open reading frames (6–8). In adult women, the longest AMHR2 transcript codes for a 568 amino acid protein containing a 125 amino acid extracellular ligand-binding domain (7, 8). AMHR2 signaling causes regression of the Müllerian ducts during male fetal development and regulates oocyte development and follicle production in adult females, thereby providing substantial control of ovarian reserve and fertility (6, 9–11).

Here, we show that in normal human tissues, AMHR2-ED is expressed exclusively in the ovary, that AMHR2-ED expression declines dramatically in the postmenopausal human ovary and in the related aged murine ovary, and that AMHR2-ED is expressed in approximately 90% of human EOC. Moreover, our preclinical studies in mice show that AMHR2-ED vaccination induces safe and effective prevention and treatment of murine EOC and that this induced tumor immunity is accompanied by a surprisingly mild and transient oophoritis in young mice vaccinated at 8 weeks of age and by no detectable inflammatory ovarian changes in old mice vaccinated at 9 months of age. We found that active vaccination and specific IgG targeting of AMHR2-ED induces proinflammatory immune responses, resulting in growth arrest and apoptotic cell death of murine EOC in vivo and in vitro. Our data support the view that AMHR2-ED vaccination not only provides effective immunotherapy against EOC, but also has the potential to provide safe and effective primary immunoprevention of this disease in women at high genetic or familial risk and in cancer-free postmenopausal women who account for the majority of EOC cases.

Materials and Methods

Generation of recombinant mouse AMHR2-ED

The DNA-coding sequence of the entire 125 amino acids of the mature native AMHR2 extracellular domain lacking the signal peptide was used to generate the expression construct (NCBI Reference Sequence: NM_144547.2; Uniprot Q8K592; ref. 12). To optimize protein folding and enhance overall yield, substitutions for native codon sequences were made (Dapcel), and the optimized DNA was synthesized de novo to include an N-terminal methionine immediately followed by a FLAG tag, and a C-terminal 6xHis tag. The construct was inserted into the NdeI-BamHI sites of pET3a (GeneArt), thereby providing a recombinant dual-tagged AMHR2-ED protein. Plasmids containing these inserts were transformed in BL21 Star E. coli (Thermo Fisher Scientific), and after induction with isopropyl-β-D thiogalactopyranoside (IPTG; Amresco), high-level expression colonies were selected and sequenced to confirm proper gene orientation and alignment. The 6xHis-tagged AMHR2-ED was purified under denaturing conditions using nickel-nitrilo triacetic acid (Ni-NTA) affinity chromatography (Qiagen). The purified protein was electrophoresed on denaturing SDS-PAGE gels (Bio-Rad) and blotted onto immunblot PVDF membrane (Bio-Rad). Immune detection of AMHR2-ED was performed using the enhanced chemiluminescence system (Amersham Biosciences) with HRP-conjugated Penta-His antibody (Qiagen). Prior to use in vitro, the 6xHis-tagged AMHR2-ED was further purified by reverse-phase HPLC or treated with endotoxin removal beads (Miltenyi Biotec) to yield endotoxin-free protein (13). Levels of endotoxin were determined to be <0.05 endotoxin units (<5 pg) per mg recombinant protein.

Mice and vaccination

TgMlSIIR-Tag (DR26) and TgMlSIIR-Tag (low) transgenic mice were generously provided by Dr. Denise C. Connolly, Developmental Therapeutics Program, Fox Chase Cancer Center (Philadelphia, PA). Female TgMISIIR-Tag (DR26) transgenic mice develop bilateral autochthonous EOC due to expression of the large T antigen (Tag) of SV40 under control of the AMHR2 promoter (14). TgMISIIR-Tag (low) transgenic female mice do not develop autochthonous EOC due to errant transgene insertion, but these mice are immunologically tolerant to SV40-TAg and effectively serve as histocompatible recipients of transplantable tumors derived from TgMlSIIR-Tag (DR26) mice (15). Colonies of transgenic mice were established and maintained by breeding male transgenic mice with wild-type syngeneic C57BL/6 females (The Jackson Laboratory). BALB/c, FVB/NJ, and A/J female mice were obtained commercially (The Jackson Laboratory). Mice were immunized at 8 weeks of age by a single subcutaneous injection in the abdominal flanks with 100 μg recombinant mouse AMHR2-ED or grade 7 ovalbumin (Sigma-Aldrich) in 200 μL of an emulsion of equal volumes of water and complete Freund's adjuvant (CFA; Difco) containing 200 μg of Mycobacterium tuberculosis H37Ra. For therapeutic intervention, TgMISIIR-Tag (DR26) mice were vaccinated with AMHR2-ED when tumors emerged and became palpable at 3 months of age.

Generation of a primary mouse ovarian carcinoma (MOVCAR) cell line

MOVCAR cells were generated from TgMISIIR-Tag (DR26) ascites fluid as described previously (15). Briefly, ascites fluid from EOC-bearing mice was washed with sterile cold PBS to lyse red blood cells, and the pelleted cells were cultured in T75 flasks (BD Biosciences) in DMEM (Cell-Services Media, Cleveland Clinic, Cleveland, OH) supplemented with 5% FBS (HyClone), 0.005 mg/mL bovine insulin (Sigma-Aldrich), 5% HEPES buffer (Sigma-Aldrich), 2 mmol/L l-glutamine (Thermo Fisher Scientific), and 1% penicillin/streptomycin (Invitrogen). After overnight incubation at 37°C in 5% CO2, adherent cells were trypsinized, washed thoroughly in PBS, and recultured with fresh supplemented media for several days until adherent monolayers formed. Adherent cells were trypsinized again, washed in PBS, and seeded with fresh supplemented media in T75 flasks for repeated passage at 3–4 day intervals until the cells became morphologically consistent and ready for inoculation into TgMISIIR-Tag (low) recipients. MOVCAR cells were periodically tested to be Mycoplasma free and their passage number did not exceed 15.

Transplantable ovarian tumors

MOVCAR cells were suspended in PBS, and 4 × 106 cells were injected subcutaneously in a total volume of 100 μL in the left dorsal flank of TgMISIIR-Tag (low) female mice. Tumor growth was assessed regularly using a Vernier caliper and the endpoint for all experiments involving transplantable tumors was defined by a tumor measurement of 17 mm in any direction.

In vivo measurement of autochthonous ovarian tumors

Bilateral ovarian tumor growth in TgMISIIR-Tag (DR26) female mice was measured monthly using the Vevo 770 high-resolution in vivo micro-imaging system for small animal imaging (VisualSonics) as described previously (16). Measurements and calculations of tumor areas were performed using the Vevo software B-Mode measurement tool allowing for a 2D assessment of ovarian tumor size in vivo with the polygon region of interest setting (VisualSonics). Measurements of solid tumor size by B-mode sonography has been shown to correlate well with histologic measurements (17).

qRT-PCR and Western blot analysis

Tissues were excised and stored frozen in RNA-Later (AM7021, Life Technologies). RNA was either extracted from each tissue by homogenization in TRIzol reagent (Invitrogen) or purchased commercially (OriGene Technologies; and ILS Biotech). Gene expression was measured by qRT-PCR using SYBR Green PCR Mix (43098155, Applied Biosystems) with gene-specific primer pairs (Invitrogen; Table 1). Relative gene expression for each test gene was determined by normalization to β-actin expression in each tissue sample.

View this table:
  • View inline
  • View popup
Table 1.

Primer pairs used for transgene detection and qRT-PCR

Transgene expression in offspring of transgenic mice was determined by PCR amplification as described previously (Table 1; ref. 16). Western blot analysis of human ovarian tissues was performed as described previously (16) using a rabbit polyclonal primary antibody specific for AMHR2-ED (Santa Cruz Biotechnology) or a mouse mAb specific for β-actin (Sigma-Aldrich). Detection was facilitated using secondary antibodies specific for rabbit and mouse IgG (Southern Biotech).

ELISPOT assays

Four weeks after vaccination, splenocytes, CD4+ T cells, and CD8+ T cells were cultured in triplicate at 2 × 105 cells per well in 96-well multi-screen HTS plates (EMD Millipore), precoated overnight with 4 μg/mL purified capture antibodies specific for mouse IFNγ, IL17A (eBioscience), and IL5 (BD Biosciences). Cells were cultured with 50 μg/mL of test and control antigens in a total volume of 200 μL DMEM supplemented with 10% FBS (Thermo Fisher Scientific), 5% HEPES buffer (Sigma-Aldrich), 2 mmol/L l-glutamine (Thermo Fisher Scientific), and 1% penicillin/streptomycin (Invitrogen). Positive control wells contained 2 μg/mL mouse CD3 antibody (BD Biosciences), and negative control wells contained 50 μg/mL recombinant mouse β-casein, a recombinant protein antigen generated in E. coli in a manner similar to AMHR2-ED. CD4+ and CD8+ T cells were positively enriched (>90% purity) from splenocytes by magnetic bead separation using a MidiMACS cell separator (Miltenyi Biotec). Cultures with purified CD4+ or CD8+ T cells were supplemented with 1 × 105 γ-irradiated (20 Gy) syngeneic splenocyte feeder cells to facilitate antigen presentation. ELISPOTs were processed as reported previously (16), and spots were counted using an ImmunoSpot S6 analyzer with proprietary ImmunoSpot 5.1 software (Cellular Technologies Limited). T-cell frequencies are expressed as spot-forming units per 1 × 106 cells.

ELISA assays

Total serum IgG titers to AMHR2-ED were determined by serial dilutions of sera in 96-well plates as described previously (16). Isotype-specific serum antibody titers to AMHR2-ED were determined according to the manufacturer's instructions using the Mouse Typer Isotyping Panel (Bio-Rad).

IHC

Immunostaining for tissue detection of T cells was performed as described previously (16). Briefly, CD3+ T cells were immunostained in 5-μm sections of formalin-fixed paraffin-embedded ovarian tissues using a 1/500 dilution of rat anti-mouse CD3 (AbD Serotec; clone CD3-12), followed by a 1/1,000 dilution of biotinylated goat anti-rat IgG (Vector Laboratories). CD4+ and CD8+ T cells were immunostained in 5-μm frozen sections of ovarian tumors by incubation with a 1/50 dilution of mouse CD4 or CD8 primary antibodies (BD Biosciences), followed by treatment with secondary detection antibodies using the mouse HRP-Polymer Kit (Biocare Medical). Terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) staining was performed using the TUNEL Kit (EMD Millipore Corporation), and apoptotic bodies were detected with Vina Green staining for caspase-3 using rabbit polyclonal caspase-3 antibody (R&D Systems). Visualization was achieved using the VECTASTAIN Elite ABC Kit, the DAB Substrate Kit (Vector Laboratories), hematoxylin and eosin counterstaining, and mounting of sections in Cytoseal 60 (Stephens Scientific) for examination by light microscopy. TUNEL-positive and caspase-3–positive cells were quantified using NIS-ELEMENTS-BR-version 4 software (Nikon).

Passive transfer of tumor immunity

Three weeks after vaccination of C57BL/6 females (The Jackson Laboratory) with either AMHR2-ED or grade 7 ovalbumin (Sigma-Aldrich), CD4+ T cells and B220+ B cells were enriched >90% from splenocytes by magnetic bead separation (Miltenyi Biotec). Without any prior reactivation, 2 × 107 B220+ B cells were transferred by intraperitoneal injection into naïve 8-week-old syngeneic female TgMlSIIR-Tag (low) recipient mice. Prior to transfer, CD4+ T cells were activated in vitro for 3 days with 20 μg/mL immunogen in 24-well flat-bottom Falcon plates (BD Biosciences) in a total volume of 2.0 mL/well in supplemented DMEM. A total of 2 × 107 activated CD4+ T cells were transferred into naïve recipient mice. Cell-free sera were collected 4 weeks after vaccination with either AMHR2-ED or ovalbumin, and the IgG was affinity purified from immune sera using protein G-sepharose (BioVision). TgMlSIIR-Tag (low) naïve recipients were injected intraperitoneally twice one week apart with 200 μg purified IgG in 200 μL PBS. Twenty-four hours after the final injection of cells or IgG, each TgMlSIIR-Tag (low) recipient was inoculated with 4 × 106 MOVCAR cells, and tumor growth was evaluated as described above. Prior to transfer, purities of enriched lymphocytes were determined by flow cytometry using a FACSAria II flow cytometer (BD Biosciences), and results were analyzed using FlowJo software (FlowJo).

Isolation of tumor-infiltrating lymphocytes

Autochthonous EOCs from TgMISIIR-Tag (DR26) mice vaccinated with CFA or AMHR2-ED were digested for 30 minutes at 37°C in DMEM containing 50 KU of DNase I (Sigma-Aldrich) and 0.2 mg/mL collagenase II (Thermo Fisher Scientific). Prior to use in ELISPOT assays, tumor-infiltrating lymphocytes (TIL) were negatively enriched by passage of the isolated leukocytes through nylon wool fiber.

MTS assay, trypan blue exclusion assay, and Annexin V FITC staining

Affinity-purified IgGs from sera of AMHR2-ED vaccinated and CFA vaccinated control mice were tested in three different in vitro assays for the ability to arrest growth and induce apoptosis of murine EOC cells. MOVCAR cells at 1 × 104 cells/microtiter well in 50 μL media were incubated for 72 hours with varying dilutions (1/200, 1/500, and 1/1,000) of IgG. The MTS assay was performed using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega) according to the manufacturer's instructions. The bioreduction of the MTS tetrazolium compound by live cells into a soluble colored formazan product measured by absorbance at 490 nm is directly proportional to the number of living cells in culture (18). To confirm the results obtained from MTS assays, MOVCAR cell viability was determined by trypan blue exclusion by counting 200 cells per field for each sample of IgG-treated cells. In addition, apoptotic MOVCAR cells from the IgG-treated cultures were quantified by flow cytometry using the FITC Annexin V Apoptosis Detection Kit (BD Biosciences).

Fertility assessments

To determine fertility phenotypes as an assessment of ovarian function, age-matched AMHR2-ED and CFA control vaccinated C57BL/6 female mice were mated serially with the same C57BL/6 male partners over several mating cycles. Fertility efficiency of the vaccinated female mice was assessed by examining mean number of pups per litter and mean pup birth weights.

Biostatistical analysis

Differences between mRNA expression levels were compared using the Student t test and two-way ANOVA. Differences in ELISPOT frequencies and tumor size were compared using two-way ANOVA. Differences in fertility, growth arrest, and frequencies of trypan blue–positive and Annexin V–positive apoptotic cells were compared using the unpaired Student t test. Differences in mouse survival were determined by log-rank and χ2 using correlated samples. Differences in TUNEL staining and caspase-3 positive scoring were assessed using the two sample Student t test. All experiments were repeated 3 times independently.

Study approval

All protocols for animal research met with the prior approval of the Institutional Animal Care and Use Committee of the Cleveland Clinic (IACUC) in compliance with the Public Health Service policy on humane care and use of laboratory animals (IACUC #2015-1390 and IACUC #2016-1585). All human tissues examined were obtained and examined with prior approval from the Internal Review Board (IRB) of the Cleveland Clinic (IRB 12–1404) as exempt research involving use of existing data without recording subject identifiers.

Results

AMHR2 gene expression in human tissues

Although ovarian expression of AMHR2 is well documented, extraovarian AMHR2 transcripts are known to be expressed in other adult human tissues most notably adrenal gland, spleen, pancreas, and skeletal muscle (Fig. 1A; refs. 4–6). However, none of these nonovarian AMHR2 transcripts code for exons 1–3 representing the entire extracellular ligand-binding domain for anti-Müllerian hormone (AMH; Fig. 1B; refs. 6–8). We confirmed these published observations by showing that the adrenal gland and pancreas express the cytoplasmic domain of AMHR2 (AMHR2-CD) but that AMHR2-ED expression is confined to the ovary (Fig. 1C). In addition, we also found that human postmenopausal ovaries (mean, 64 years; range, 52–95 years) and comparable old mouse ovaries (9 months of age) have significantly lower AMHR2-ED expression levels when compared respectively with human premenopausal ovaries (mean, 31 years; range, 27–45 years) and young mouse ovaries (6 weeks of age; Fig. 1D; P < 0.0001 for both human and mouse ovaries). Moreover, all human EOCs examined showed high-level expression of AMHR2-ED transcripts assessed by qRT-PCR (Fig. 1E) and substantial AMHR2-ED protein levels assessed by Western blot analysis (Fig. 1F).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

AMHR2 gene expression in human tissues. A, Highest levels of human AMHR2 gene expression occur in the ovary and adrenal gland with substantially lower levels in the spleen, pancreas, and skeletal muscle. Data indicate mean fragments per kilobase of transcript per million mapped reads (FPKM) from 2 to 5 samples analyzed from each tissue derived from the Human Protein Atlas (6). B, The four known AMHR2 transcripts having protein-coding domains are depicted with schematic representative FPKM from each of the 5 human tissues expressing detectable levels of AMHR2. Transcripts coding the extracellular domain of human AMHR2 (exons 1–3) are expressed exclusively in the ovary. Data are derived directly from the Human Protein Atlas (6). C, qRT-PCR analysis of human tissues confirms findings from the Human Protein Atlas by showing that AMHR2-ED is expressed exclusively in the human ovary and is not expressed in the human adrenal gland or pancreas. D, Ovarian AMHR2-ED gene expression declines with age and is significantly lower in the postmenopausal ovary (mean age, 64 years) compared with the premenopausal ovary (mean age, 31 years). A similar significant decline in AMHR2-ED gene expression occurs in senescent mouse ovaries (9 months of age). The decline with age in ovarian expression of AMHR2 stands in contrast to the high level of gene expression of both AMHR2-CD and AMHR2-ED domains in human EOC (E). F, The high AMHR2 gene expression levels in human EOC are concurrent with high levels of detectable AMHR2 protein determined by Western blot analysis on all 16 human EOCs examined. In all cases, error bars indicate ±SD, and asterisks indicate significance.

Generation of recombinant mouse AMHR2-ED and assessment of its immunogenicity

To determine whether AMHR2-ED has the potential to target safe and effective EOC immunoprevention, we generated a recombinant protein spanning the entire 125 amino acids of the mature mouse AMHR2 extracellular domain (Fig. 2A and B). We found that our recombinant AMHR2-ED protein migrated as a single band on SDS-PAGE when detected by Coomassie blue staining (Fig. 2C, left) or anti-His Western blot (Fig. 2C, right). One month after AMHR2-ED vaccination of young 8-week-old C57BL/6 female mice, ELISPOT analysis showed elevated splenocyte frequencies of IFNγ-producing antigen-specific T cells at a mean of 1 per 3,831 splenocytes, and IL17 at a mean of 1 per 21,739 splenocytes, but not IL5 (Fig. 2D). The proinflammatory T cells responding to AMHR2-ED were predominantly CD4+ T cells but also included a minor CD8+ T-cell population producing IFNγ (Fig. 2E) or IL17 (Fig. 2F). Four months after AMHR2-ED vaccination, serum IgG antibody responses against AMHR2-ED were detectable at dilutions up to 1/50,000 (Fig. 2G) and consisted predominantly of IgG1 and IgG2b isotypes (Fig. 2H). AMHR2-ED was highly immunogenic in several mouse strains with completely divergent MHC H-2 haplotypes, including C57BL/6 (H-2b), BALB/c (H-2d), A/J (H-2a), and FVBN/J (H-2q) in which IFNγ-secreting splenocytes reached mean frequencies of 1 per 4,310, 1 per 4,425, 1 per 8,772, and 1 per 10,000, respectively, at one month after vaccination (Fig. 2I).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Generation of recombinant mouse AMHR2-ED and assessment of its immunogenicity. A, Single-letter amino acid sequence of our generated recombinant mouse AMHR2-ED protein showing the N-terminal methionine start site and FLAG-tag, followed by the 125 amino acid sequence of the mouse AMHR2-ED sequence followed by a C-terminal 6xHis tag. B, Diagrammatic representation of the native domains of the full-length sequence of the mouse AMHR2 protein (top) and the 125 amino acid extracellular domain used as immunogen (bottom). C, After Ni-NTA affinity purification, AMHR2-ED protein was loaded at two doses and migrated as single bands on SDS-PAGE as detected by Coomassie blue stain (left) and anti-His Western blot (right). D, One month after AMHR2-ED vaccination of 8-week-old female C57BL/6 mice, ELISPOT analysis showed elevated splenocyte frequencies of antigen-specific T cells producing IFNγ and IL17 but not IL5. The IFNγ (E) and IL17 (F) proinflammatory response to AMHR2-ED was elicited predominantly from CD4+ T cells. G and H, AMHR2-ED vaccination induced a substantial serum IgG antibody response against AMHR2-ED that was detectable at dilutions up to 1/50,000 (G) and this IgG response predominantly involved the IgG1 and IgG2b isotypes (H). I, The immunogenicity of AMHR2-ED was not confined to C57BL/6 mice as female mice representing three other divergent H-2 haplotypes showed high antigen-specific frequencies of IFNγ-producing T cells. In all cases, error bars indicate ±SD.

AMHR2-ED vaccination inhibits growth of transplantable and autochthonous murine EOC

We next determined whether vaccination with AMHR2-ED could inhibit the growth of murine EOC. We found that prophylactic AMHR2-ED vaccination 15 days (Fig. 3A; P < 0.001) or 7 days (Fig. 3B; P < 0.001) prior to MOVCAR inoculation of TgMISIIR-TAg (low) transgenic mice resulted in significant inhibition in the growth of transplantable EOC when compared with control mice vaccinated with CFA alone. Similarly, prophylactic AMHR2-ED vaccination of 6–7-week-old TgMISIIR-Tag (DR26) transgenic mice delayed the appearance and significantly inhibited the growth of autochthonous EOC compared with control mice vaccinated with CFA alone (Fig. 3C; P < 0.0001). This inhibition in the emergence and growth of autochthonous EOC resulted in a highly significant 42% increase in mean overall survival (P < 0.0001) compared with control mice vaccinated with CFA alone (mean 194 ± 35 days vs. mean 135 ± 14 days, respectively; Fig. 3D). AMHR2-ED vaccination was also effective in providing highly significant immunotherapy against EOC in TgMISIIR-Tag (DR26) transgenic mice with established growing autochthonous EOC (Fig. 3E; P < 0.001). IHC analysis of autochthonous EOC from TgMISIIR-Tag (DR26) mice vaccinated with AMHR2 consistently showed prominent infiltrates (shown by arrows) of CD3+ T cells (Fig. 3F, top left) and CD4+ T cells (Fig. 3F, middle left) with occasional CD8+ T cells (Fig. 3F, bottom left). Corresponding immunostained EOC from control mice vaccinated with CFA alone consistently failed to show detectable T-cell infiltrates (Fig. 3F, right). TILs from EOC taken from AMHR2-ED vaccinated TgMISIIR-Tag (DR26) mice showed significantly higher ELISPOT frequencies of IFNγ (Fig. 3G; P = 0.0001) and IL17 (Fig. 3H; P = 0.0001) producing T cells in recall responses to AMHR2-ED compared with TILs from control mice vaccinated with CFA alone.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

AMHR2-ED vaccination inhibits growth of transplantable and autochthonous murine EOC. Prophylactic AMHR2-ED vaccination 15 days (A) and 7 days (B) prior to MOVCAR inoculation of TgMISIIR-Tag (low) transgenic mice resulted in significant inhibition in the growth of transplantable EOC. C, Similarly, prophylactic AMHR2-ED vaccination of 6–7-week-old TgMISIIR-Tag (DR26) transgenic mice significantly delayed the appearance and growth of autochthonous EOC. D, The inhibition in growth of autochthonous tumors resulted in a highly significant 42% increase in mean overall survival. E, AMHR2-ED vaccination was also effective in providing significant immunotherapy against EOC in TgMISIIR-Tag (DR26) transgenic mice with established autochthonous tumors. F, IHC analysis of autochthonous EOC from AMHR2-ED vaccinated TgMISIIR-Tag (DR26) mice showed prominent diffuse infiltrations of CD3+ T cells (top left) and CD4+ T cells (middle left) but only occasional isolated CD8+ T cells (bottom left) indicated by arrows. In contrast, control vaccinated mice never showed any T-cell infiltrates (right). TILs from autochthonous EOC taken from AMHR2-ED vaccinated TgMISIIR-Tag (DR26) mice showed elevated frequencies of AMHR2-ED–specific T cells producing IFNγ (G) and IL17 (H) in recall responses compared with TILs isolated from EOC taken from control vaccinated mice. Data in G and H represent one of three experiments yielding similar results. In all cases, error bars indicate ±SD, and asterisks indicate significance.

Passive transfer of tumor immunity with CD4+ T cells, B220+ B cells, and IgG

We next determined which immune population accounted for inhibition of EOC growth. We found that transfer of AMHR2-ED primed CD4+ T cells into TgMISIIR-Tag (low) female mice one day prior to MOVCAR inoculation resulted in highly significant inhibition of tumor growth (Fig. 4A; P < 0.0001) and enhanced overall survival (Fig. 4B; P < 0.006) compared with mice receiving ovalbumin primed CD4+ T cells. Moreover, transfer of AMHR2-ED primed B220+ B cells into TgMISIIR-Tag (low) female mice one day prior to MOVCAR inoculation also mediated significant inhibition of tumor growth (Fig. 4C; P < 0.0001) and enhanced overall survival (Fig. 4D; P < 0.009) compared with mice receiving B220+ B cells from ovalbumin immunized mice. In addition, transfer of affinity-purified IgG from AMHR2-ED immunized mice into TgMISIIR-Tag (low) female mice one day prior to MOVCAR inoculation resulted in significant inhibition of tumor growth (Fig. 4E; P < 0.0001) and enhanced overall survival (Fig. 4F; P < 0.002) compared with mice receiving affinity-purified IgG from ovalbumin immunized mice.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Passive transfer of tumor immunity with CD4+ T cells, B220+ B cells, and IgG. A and B, Transfer of AMHR2-ED primed CD4+ T cells into TgMISIIR-Tag (low) female mice one day prior to MOVCAR inoculation resulted in significant inhibition of tumor growth (A) and enhanced overall survival compared with mice receiving ovalbumin primed CD4+ T cells (B). C and D, Similar transfer of AMHR2-ED primed B220+ B cells also resulted in significant inhibition of tumor growth (C) and enhanced overall survival (D). E and F, Likewise, transfer of affinity-purified IgG from AMHR2-ED immunized mice also resulted in significant inhibition of tumor growth (E) and enhanced overall survival (F). In all cases, error bars indicate ±SD, and asterisks indicate significance.

AMHR2-ED vaccination and IgG treatment induces metabolic arrest and apoptosis of murine EOC

IHC analysis of autochthonous EOC from TgMISIIR-Tag (DR26) mice vaccinated with AMHR2-ED showed a diffuse distribution of TUNEL-positive cells (Fig. 5A, top left) and caspase-3–positive cells (Fig. 5A, bottom left) compared with EOC from control vaccinated mice (Fig. 5A, middle). The differences in frequencies of these apoptotic tumor cells between both vaccinated groups were significant (Fig. 5A, right; P = 0.005 for TUNEL and P = 0.0007 for caspase-3). In addition, qRT-PCR analysis showed that the increased frequencies of apoptotic tumor cells in AMHR2-ED vaccinated mice occurred in the presence of significantly increased expression of the proapoptotic Bax gene compared with EOC from control vaccinated mice (Fig. 5B; P < 0.0001). No differences were evident in gene expression of prosurvival Bcl2 or in expression of other proapoptotic genes, including Bak and Bim (Fig. 5B). We next determined whether the apoptosis occurring in EOC from AMHR2-ED vaccinated mice may be mediated by IgG. To this end, we found that treatment of MOVCAR cells for 72 hours with IgG purified from sera taken from AMHR2-ED vaccinated TgMISIIR-Tag (DR26) mice resulted in pronounced metabolic arrest as measured by the MTS assay (Fig. 5C; P = 0.02) and in corresponding apoptotic cell death as measured by trypan blue exclusion (Fig. 5D; P = 0.01) and by cell surface expression of Annexin V (Fig. 5E; P = 0.06).

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

AMHR2-ED vaccination and IgG treatment induces metabolic arrest and apoptosis of murine EOC. A, IHC analysis of autochthonous EOC from AMHR2-ED vaccinated TgMISIIR-Tag (DR26) mice showed a diffuse distribution of numerous TUNEL-positive EOC cells (top left) compared with control vaccinated mice (top middle). Quantification of TUNEL-positive EOC cells showed significantly increased frequencies in mice vaccinated against AMHR2-ED (top right; n = 3). Similarly, AMHR2-ED vaccinated TgMISIIR-Tag (DR26) mice showed diffusely distributed caspase-3–positive EOC cells (bottom left) compared with control vaccinated mice (bottom middle), and quantification of caspase-3–positive EOC cells showed significantly increased frequencies in mice vaccinated against AMHR2-ED (bottom right; n = 3). B, qRT-PCR analysis of EOC from AMHR2-ED vaccinated TgMISIIR-Tag (DR26) mice showed significantly elevated gene expression for proapoptotic Bax but not for the other proapoptotic genes, Bim or Bak or for the prosurvival Bcl2 gene compared with tumors from control vaccinated mice. Treatment of MOVCAR cells with IgG purified from sera of AMHR2-ED vaccinated TgMISIIR-Tag (DR26) mice resulted in (C) pronounced metabolic arrest as measured by the MTS assay and in corresponding apoptotic cell death as measured by (D) trypan blue exclusion and (E) cell surface expression of annexin V compared to treatment with IgG from control vaccinated mice. In all cases, error bars indicate ±SD, and asterisks indicate significance.

AMHR2-ED vaccination induces benign and transient autoimmune effects

We next assessed the autoimmune phenotype resulting from AMHR2-ED vaccination. Four weeks after AMHR2-ED vaccination of young 8-week-old C57BL/6 female mice, qRT-PCR analysis of ovarian tissues showed significantly elevated gene expression for IL1β but not for IFNγ when compared with control mice vaccinated with CFA alone (Fig. 6A; P = 0.0004). However, this elevated ovarian expression of inflammatory factors was not apparent by 8 weeks after vaccination (Fig. 6B). In contrast, AMHR2-ED vaccination of 9-month-old C57BL/6 mice did not result in any elevated ovarian expression of either IL1β or IFNγ at both 4 weeks (Fig. 6C; P > 0.40) and 8 weeks (Fig. 6D; P > 0.40) after vaccination. It is important to note that the transient increase in ovarian expression of IL1β after AMHR2-ED vaccination of young mice had rather benign consequences as it was not associated with any detectable changes in fertility over four mating cycles as measured by either mean number of pups/litter (Fig. 6E; P > 0.40) or mean pup birth weight (Fig. 6F; P > 0.40). It is also worth noting that splenocyte frequencies of AMHR2-ED–specific IFNγ-producing and IL17-producing T cells were actually higher in 9-month-old mice 2 months after AMHR2-ED vaccination (1 per 2,762 and 1 per 14,085 splenocytes, respectively) compared with frequencies of 8-week-old mice 1 month after vaccination (1 per 3,831 and 1 per 21,739 splenocytes, respectively; data not shown). This substantial immune response elicited in 9-month-old mice precludes aged-based decreased immunity as an explanation for the qualitative differences observed in gene expression of ovarian inflammatory factors in young versus old ovaries and most likely reflects the age-related dramatic decline in expression of AMHR2-ED that occurs in both murine and human ovaries (Fig. 1D).

Figure 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6.

AMHR2-ED vaccination induces benign and transient autoimmune effects. A, Four weeks after AMHR2-ED vaccination of young 8-week-old C57BL/6 female mice, qRT-PCR analysis showed elevated ovarian gene expression of IL1β but not IFNγ when compared with mice vaccinated with CFA alone. B, The increased ovarian gene expression of IL1β was not evident 8 weeks after vaccination of young 8-week-old mice. In contrast, AMHR2-ED vaccination failed to induce any increased ovarian gene expression of IL1β or IFNγ gene expression at either 4 weeks (C) or 8 weeks (D) after vaccination of 9-month-old C57BL/6 female mice. The transient detection of ovarian inflammation in young vaccinated mice was not accompanied by any differences in fertility over four mating cycles as measured by both mean number of pups/litter (E) and mean pup birth weights (F). In all cases, error bars indicate ±SD.

Discussion

Our data indicate that AMHR2-ED vaccination significantly inhibits EOC growth and does so whether vaccination occurs in prophylactic or therapeutic settings. In addition, when used prophylactically in transgenic mice engineered to develop EOC, AMHR2-ED vaccination provides a dramatic 42% enhanced overall survival (Fig. 3D; P < 0.0001). Control of EOC in young fertile mice vaccinated against AMHR2-ED occurs in the presence of mild and transient ovarian inflammatory changes that produce no detectable longlasting adverse effects on ovarian function as determined by stable fertility over several mating cycles. As normal tissue expression of AMHR2-ED is confined exclusively to the ovary, and as approximately 90% of human EOC express AMHR2-ED, vaccination against AMHR2-ED has the appeal of providing immunotherapy against EOC with substantially reduced risk of systemic autoimmune complications. This reduced risk provides a marked safety advantage over more ubiquitously expressed self-proteins that have been proposed as vaccine targets for EOC immunotherapy, including HER2, folate receptor alpha, tumor protein p53, cancer antigen 125, mucin 1 (MUC-1), and mesothelin (reviewed in ref. 19).

Reducing risk of systemic autoimmunity is certainly a desirable feature for any immunotherapeutic strategy. However, the dramatic decline in AMHR2-ED expression in older human and mouse ovaries and the lack of any detectable autoimmune oophoritis following AMHR2-ED vaccination of aged mice supports the view that AMHR2-ED vaccination of postmenopausal women may likely occur in the absence of any substantial tissue-specific ovarian autoimmunity. Thus, the decreased risk for inducing ovarian and systemic autoimmunity in aging females indicates the feasibility of achieving safe and effective primary immunoprevention of EOC in postmenopausal women who account for >75% of all EOC cases (1, 2).

In the United States, menopause occurs in women at a mean age of 51 years and indicates cessation in production of mature ovarian follicles, ovulation, and fertilization (20). This age-related event has long been associated with dramatic declines in serum levels of the AMH hormone (21). Indeed, undetectable serum levels of AMH are also associated with primary ovarian insufficiency (POI), a fertility disorder that afflicts young women in their childbearing years (22). Thus, declining levels of AMH have been proposed as a way to assess the development and progression of ovarian senescence (22). Our data indicate that a substantial decline in ovarian expression of AMHR2-ED is also associated with menopause and suggests that decreased expression of AMHR2-ED may also be involved in the etiopathogenesis of POI. This dual decline in production of both AMH ligand and its cognate receptor-binding domain appears to confirm exhaustion of the ovarian reserve and cessation in production of mature fertile follicles that are known to be regulated by AMH/AMHR2 signaling (23).

Currently, seven human AMHR2 transcripts have been identified, but only four of these transcripts code for known protein variants and only one of these four transcripts codes for the extracellular domain transcribed from exons 1–3 (Fig. 1B; ref. 6). The full-length transcript coding for the extracellular domain is found exclusively in the ovary, although transcripts coding for the human kinase domain are expressed at high levels in the adrenal gland and at somewhat lower levels in the spleen, pancreas, and skeletal muscle (Fig. 1A; 6, 24–27). It is unclear why protein variants of AMHR2 that do not contain the cognate receptor-binding domain for AMH are expressed in extraovarian tissues. Perhaps transcripts missing the extracellular domain provide transcriptional regulatory functions as has been proposed (28). Alternatively, it is feasible that the cytoplasmic serine/threonine kinase of AMHR2 may be accessed in nonovarian tissues through currently unknown alternative signaling pathways. In any event, the expression of the cytoplasmic domain in extraovarian tissues and its failure to decline significantly in expression in the aging ovary (Fig. 1D) preclude its safe use as a vaccine target for primary immunoprevention of EOC despite its substantial effectiveness as a vaccine target for EOC immunotherapy in preclinical studies (16).

It is noteworthy that immunity against EOC could be transferred into naïve recipients with either CD4+ T cells, B cells, or IgG specific for AMHR2-ED. This implies that both cellular and humoral immune mechanisms are involved in the ability of AMHR2-ED vaccination to mediate inhibition of EOC growth. Indeed, our data indicate that AMHR2-ED–specific IgG alone is fully capable of mediating inhibition of EOC growth in vivo (Fig. 4E and F) and cell-cycle arrest and apoptotic death of EOC in vitro (Fig. 5B–E). Thus, we propose that AMHR2-ED vaccination inhibits the growth of EOC through the helper function of CD4+ T cells that facilitates B cells to produce AMHR2-ED–specific IgG. The IgG agonizes a Bax/caspase-3–dependent proapoptotic signaling cascade known to inhibit tumor growth (29). The lack of increased gene expression of the proapoptotic Bim implies that the cell death signal may be mediated by binding of the proapoptotic Bid protein to Bax in the “indirect” apoptosis activation model (30). Alternatively, Bax may be activated directly by other proapoptotic proteins like p53 or Diva (31, 32). Studies are currently under way to determine the underlying apoptotic signaling elements as well as any antibody-independent roles played by B cells and CD4+ T cells in the inhibition of EOC growth induced by AMHR2-ED vaccination.

There are many hurdles to overcome before AMHR2-ED vaccination undergoes testing in clinical trials, not the least of which is the selection of an appropriate adjuvant. Although CFA has been most useful in preclinical proof-of-principle studies for over 70 years, its potential for generating unresolved granulomas makes it unacceptable for use in human vaccination (33). For inducing tumor prophylaxis, candidate adjuvants may best be selected on the basis of how well they mimic the features of CFA in inducing T cells from both Th1 and Th17 proinflammatory lineages each independently associated with severe autoimmune tissue damage (34). Thus, the requirements for optimized tumor immunoprevention may be substantially different from those needed for optimized tumor immunotherapy where inflammatory mediators induced by IL17 may facilitate the production of angiogenic and antiapoptotic factors that enhance the growth of established tumors (35).

Recently, primary immunoprevention has been referred to as the “holy grail” and the “great unmet need” for the control of adult onset cancers (36, 37). Indeed, several approaches to accomplish this goal have been proposed, including targeting of a variety of self-proteins, frameshift neoantigens, and viruses believed to be overexpressed in adult onset tumors (reviewed in ref. 37). Certainly, immunotherapy has already achieved breakthrough status in cancer control (38). Perhaps primary immunoprevention of adult onset cancers may soon break through as well.

Disclosure of Potential Conflicts of Interest

S. Mazumder has ownership interest (including patents) in Shield Biotech, Inc. J.M. Johnson has ownership interest (including patents) in Shield Biotech, Inc. V.K. Tuohy reports receiving a commercial research grant from and has ownership interest (including patents) in Shield Biotech, Inc. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: S. Mazumder, V.K. Tuohy

Development of methodology: S. Mazumder, J.M. Johnson, J. Ko, V.K. Tuohy

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Mazumder, E. Martelli, J. Ko

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Mazumder, E. Martelli, V.K. Tuohy

Writing, review, and/or revision of the manuscript: S. Mazumder, J.M. Johnson, V.K. Tuohy

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Mazumder, J.M. Johnson, V. Swank, N. Dvorina, J. Ko

Study supervision: V.K. Tuohy

Grant Support

V. K. Tuohy received support for this work in the form of a sponsored research grant from Shield Biotech, Inc., Cleveland, OH, a privately owned company.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Acknowledgments

The authors express their gratitude to Dr. Sathyamangla V. Naga Prasad, Department of Molecular Cardiology, Cleveland Clinic, Cleveland, OH, for facilitating high-resolution in vivo imaging of mouse ovarian tumors. The authors also express their thanks to Dennis Wilk, Shield Biotech, Inc., Cleveland, OH, for his assistance in purification of the recombinant proteins, and to Dr. Ritika Jaini and Mathew G. Loya, Department of Genomic Medicine, Cleveland Clinic, Cleveland, OH, for their technical assistance. Finally, the authors wish to thank Sreedevi Goparaju, Department of Immunology, Cleveland Clinic, Cleveland, OH, for her expertise in statistical analysis.

  • Received May 18, 2017.
  • Revision received September 10, 2017.
  • Accepted September 11, 2017.
  • ©2017 American Association for Cancer Research.

References

  1. 1.↵
    1. Howlader N,
    2. Noone AM,
    3. Krapcho M,
    4. Miller D,
    5. Bishop K,
    6. Altekruse SF,
    7. et al.
    editors, SEER Cancer Statistics Review, 1975-2013. Bethesda, MD: National Cancer Institute; 2016.
  2. 2.↵
    1. Siegel RL,
    2. Miller KD,
    3. Jemal A
    . Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Chang MH,
    2. Chen CJ,
    3. Lai MS,
    4. Hsu HM,
    5. Wu TC,
    6. Kong MS,
    7. et al.
    Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855–9.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Wang JW,
    2. Hung CF,
    3. Huh WK,
    4. Trimble CL,
    5. Roden RB
    . Immunoprevention of human papillomavirus-associated malignancies. Cancer Prev Res 2015;8:95–104.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Tuohy VK
    . Retired self-proteins as vaccine targets for primary immunoprevention of adult-onset cancers. Expert Rev Vaccines 2014;13:1447–62.
    OpenUrl
  6. 6.↵
    1. Josso N,
    2. di Clemente N,
    3. Gouédard L
    . Anti-Müllerian hormone and its receptors. Mol Cell Endocrinol 2001;179:25–32.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Faure E,
    2. Gouédard L,
    3. Imbeaud S,
    4. Cate R,
    5. Picard JY,
    6. Josso N,
    7. et al.
    Mutant isoforms of the anti-Müllerian hormone type II receptor are not expressed at the cell membrane. J Biol Chem 1996;271:30571–5.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Uhlén M,
    2. Fagerberg L,
    3. Hallström BM,
    4. Lindskog C,
    5. Oksvold P,
    6. Mardinoglu A,
    7. et al.
    Proteomics. Tissue-based map of the human proteome. Science 2015;347:1260419
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Baarends WM,
    2. van Helmond MJ,
    3. Post M,
    4. van der Schoot PJ,
    5. Hoogerbrugge JW,
    6. de Winter JP,
    7. et al.
    A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the müllerian duct. Development 1994;120:189–97.
    OpenUrlAbstract
  10. 10.↵
    1. Durlinger AL,
    2. Visser JA,
    3. Themmen AP
    . Regulation of ovarian function: the role of anti-Müllerian hormone. Reproduction 2002;124:601–9.
    OpenUrlAbstract
  11. 11.↵
    1. MacLaughlin DT,
    2. Donahoe PK
    . Mullerian inhibiting substance: an update. Adv Exp Med Biol 2002;511:25–38.
    OpenUrlPubMed
  12. 12.↵
    1. Mishina Y,
    2. Tizard R,
    3. Deng JM,
    4. Pathak BG,
    5. Copeland NG,
    6. Jenkins NA,
    7. et al.
    Sequence, genomic organization, and chromosomal location of the mouse Müllerian-inhibiting substance type II receptor gene. Biochem Biophys Res Commun 1997;237:741–6.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Dudley A,
    2. McKinstry W,
    3. Thomas D,
    4. Best J,
    5. Jenkins A
    . Removal of endotoxin by reverse phase HPLC abolishes anti-endothelial cell activity of bacterially expressed plasminogen kringle 5. Biotechniques 2003;35:724–6.
    OpenUrlPubMed
  14. 14.↵
    1. Connolly DC,
    2. Bao R,
    3. Nikitin AY,
    4. Stephens KC,
    5. Poole TW,
    6. Hua X,
    7. et al.
    Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003;63:1389–97.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Quinn BA,
    2. Xiao F,
    3. Bickel L,
    4. Martin L,
    5. Hua X,
    6. Klein-Szanto A,
    7. et al.
    Development of a syngeneic mouse model of epithelial ovarian cancer. J Ovarian Res 2010;3:24.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Sakalar C,
    2. Mazumder S,
    3. Johnson JM,
    4. Altuntas CZ,
    5. Jaini R,
    6. Aguilar R,
    7. et al.
    Regulation of murine ovarian epithelial carcinoma by vaccination against the cytoplasmic domain of anti-Müllerian hormone receptor II. J Immunol Res 2015;2015:630287.
    OpenUrl
  17. 17.↵
    1. Zippel D,
    2. Shalmon A,
    3. Rundstein A,
    4. Novikov I,
    5. Yosepovich A,
    6. Zbar A,
    7. et al.
    Freehand elastography for determination of breast cancer size: comparison with B-mode sonography and histopathologic measurement. J Ultrasound Med 2014;33:1441–6.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Berridge MV,
    2. Herst PM,
    3. Tan AS
    . Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 2005;11:127–52.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Chester C,
    2. Dorigo O,
    3. Berek JS,
    4. Kohrt H
    . Immunotherapeutic approaches to ovarian cancer treatment. J Immunother Cancer 2015;3:7.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Kato I,
    2. Toniolo P,
    3. Akhmedkhanov A,
    4. Koenig KL,
    5. Shore R,
    6. Zeleniuch-Jacquotte A
    . Prospective study of factors influencing the onset of natural menopause. J Clin Epidemiol 1998;51:1271–6.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Kelsey TW,
    2. Wright P,
    3. Nelson SM,
    4. Anderson RA,
    5. Wallace WH
    . A validated model of serum anti-müllerian hormone from conception to menopause. PLoS One 2011;6:e22024.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Visser JA,
    2. Schipper I,
    3. Laven JS,
    4. Themmen AP
    . Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol 2012;8:331–41.
    OpenUrlPubMed
  23. 23.↵
    1. Iwase A,
    2. Nakamura T,
    3. Nakahara T,
    4. Goto M,
    5. Kikkawa F
    . Anti-Müllerian hormone and assessment of ovarian reserve after ovarian toxic treatment: a systematic narrative review. Reprod Sci 2015;22:519–26.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Clarkson AN,
    2. Talbot CL,
    3. Wang PY,
    4. MacLaughlin DT,
    5. Donahoe PK,
    6. McLennan IS
    . Müllerian inhibiting substance is anterogradely transported and does not attenuate avulsion-induced death of hypoglossal motor neurons. Exp Neurol 2011;231:304–8.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Lebeurrier N,
    2. Launay S,
    3. Macrez R,
    4. Maubert E,
    5. Legros H,
    6. Leclerc A,
    7. et al.
    Anti-Mullerian-hormone-dependent regulation of the brain serine-protease inhibitor neuroserpin. J Cell Sci 2008;121(Pt 20):3357–65.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Wang PY,
    2. Koishi K,
    3. McGeachie AB,
    4. Kimber M,
    5. Maclaughlin DT,
    6. Donahoe PK,
    7. et al.
    Mullerian inhibiting substance acts as a motor neuron survival factor in vitro. Proc Natl Acad Sci U S A 2005;102:16421–5.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Wang PY,
    2. Protheroe A,
    3. Clarkson AN,
    4. Imhoff F,
    5. Koishi K,
    6. McLennan IS
    . Müllerian inhibiting substance contributes to sex-linked biases in the brain and behavior. Proc Natl Acad Sci U S A 2009;106:7203–8.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Imhoff FM,
    2. Yang D,
    3. Mathew SF,
    4. Clarkson AN,
    5. Kawagishi Y,
    6. Tate WP,
    7. et al.
    The type 2 anti-Müllerian hormone receptor has splice variants that are dominant-negative inhibitors. FEBS Lett 2013;587:1749–53.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Zhao G,
    2. Zhu Y,
    3. Eno CO,
    4. Liu Y,
    5. Deleeuw L,
    6. Burlison JA,
    7. et al.
    Activation of the proapoptotic Bcl-2 protein Bax by a small molecule induces tumor cell apoptosis. Mol Cell Biol 2014;34:1198–207.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Czabotar PE,
    2. Lessene G,
    3. Strasser A,
    4. Adams JM
    . Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014;15:49–63.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Chipuk JE,
    2. Kuwana T,
    3. Bouchier-Hayes L,
    4. Droin NM,
    5. Newmeyer DD,
    6. Schuler M,
    7. et al.
    Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004;303:1010–4.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Inohara N,
    2. Gourley TS,
    3. Carrio R,
    4. Muñiz M,
    5. Merino J,
    6. Garcia I,
    7. et al.
    Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death. J Biol Chem 1998;273:32479–86.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Wilson-Welder JH,
    2. Torres MP,
    3. Kipper MJ,
    4. Mallapragada SK,
    5. Wannemuehler MJ,
    6. Narasimhan B
    . Vaccine adjuvants: current challenges and future approaches. J Pharm Sci 2009;98:1278–316.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Steinman L
    . A rush to judgment on Th17. J Exp Med 2008;205:1517–22.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Hemdan NY
    . Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells. Immunol Lett 2013;149:123–33.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Nolan E,
    2. Vaillant F,
    3. Branstetter D,
    4. Pal B,
    5. Giner G,
    6. Whitehead L,
    7. et al.
    RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med 2016;22:933–9.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Tuohy VK
    . Primary immunoprevention: The great unmet need for controlling breast cancer. Oncology 2016;30:486–7.
    OpenUrl
  38. 38.↵
    1. Couzin-Frankel J
    . Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342:1432–3.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Cancer Prevention Research: 10 (11)
November 2017
Volume 10, Issue 11
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Prevention Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Müllerian Hormone Receptor II
(Your Name) has forwarded a page to you from Cancer Prevention Research
(Your Name) thought you would be interested in this article in Cancer Prevention Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Müllerian Hormone Receptor II
Suparna Mazumder, Justin M. Johnson, Valerie Swank, Nina Dvorina, Elizabeth Martelli, Jennifer Ko and Vincent K. Tuohy
Cancer Prev Res November 1 2017 (10) (11) 612-624; DOI: 10.1158/1940-6207.CAPR-17-0154

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Müllerian Hormone Receptor II
Suparna Mazumder, Justin M. Johnson, Valerie Swank, Nina Dvorina, Elizabeth Martelli, Jennifer Ko and Vincent K. Tuohy
Cancer Prev Res November 1 2017 (10) (11) 612-624; DOI: 10.1158/1940-6207.CAPR-17-0154
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • mt-sDNA Specificity in 45–49 Year-Olds
  • Targeting CD40 and PD-1/PD-L1 Inhibits OPL Progression to OSCC
  • Revisiting a clinical diagnosis of NF1 for other syndromes
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Prevention Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Prevention Research
eISSN: 1940-6215
ISSN: 1940-6207

Advertisement